The Predictability of CD19 Expression Across Primitive Cellular Fractions of Relapsed B-ALL on Outcomes of CD19-targeted CAR T-cells

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-05-20

Study Completion Date

2030-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute lymphoblastic leukemia (ALL) is a malignant proliferation of immature lymphoid cells within the bone marrow, blood, and extramedullary sites. According to the SEER Cancer Statistics Review, the incidence was estimated to be at around 1·6 per 100000 people in 2014, with around 6000 new cases diagnosed in 2018. This disease is more frequent in children aged 1-4 years, then drops reaching the lowermost point between 25 years and 45 years. Generally, around 60% of ALL cases are diagnosed before the age of 20 years. Despite significant improvements in 5-year overall survival reaching around 90% in children, only 25% of patients older than 50 years old were alive 5 years after diagnosis1,2. These survival figures are much worse when dealing with relapsed disease. Cases of relapsed or refractory ALL are usually offered allogeneic stem cell transplantation that can establish meaningful disease control after achieving the best disease control depicted in lack of measurable residual disease3. However, the inability of performing allogeneic stem cell transplantation in some patients, especially elderly patients, represents unmet needs for advancing treatment for these challenging ALL cases.

Cellular immunotherapy with CD19-directed chimeric antigen receptor (CAR) T-cells has demonstrated encouraging results for the treatment of B-cell ALL (B-ALL). Currently used CAR T-cells are genetically engineered autologous T cells that express the antigen-binding domain linked to a costimulatory molecule and an intracellular T-cell receptor signaling domain. CAR T-cells function in a major histocompatibility complex-independent manner. Because of its expression on nearly all B-ALL, CD19 became the most sensible target. This paved the way for using tisagenlecleucel and brexucabtagene autoleucel in patients with B-ALL with astonishing outcomes4-6. However, the dependence on expression of the antigen of target can be an "Achilles' heel" for CAR T-cells similar to monoclonal antibodies, and loss of this target is a major escape mechanism by which cancer cells can evade immunotherapy. Mechanisms of antigenic loss may include genetic modulations, epitope masking, or a cell lineage switch with secondary loss of the target epitope7.

Cell plasticity is the ability of cells to be reprogrammed and to alter their fate and identity, which can enable homeostasis and restoration following injury. Pathological plasticity allows cancer cells to acquire new phenotypic and/or functional features leading to disease progression and resistance to therapy8. One of the most studied and established phenotypic and functional plasticity is KMT2A-r ALL9. The seminal work of Dr. John Dick and his lab in establishing the concept of leukemia stem cell was instrumental to the field. Transplantation of human ALL into NOD/SCID mice generates a disease in these mice that is reminiscent of the human disease10. The attributes of self-renewal and clonogenic proliferation are considered "functional" markers for stemness of these leukemia initiating cells. Because some of these functional assays are laborious, multiple efforts have been exerted to uncover the most accurate markers to label these cells that cab reliably predict this unique cellular population. In addition to cell-intrinsic factors for plasticity that are mentioned above, cell-extrinsic or "niche" elements can fuel cellular plasticity when they occur. Despite these limitations, CD34+CD38- cell fraction is most likely to harbor the most primitive and quiescent cells that can fuel disease existence11.

King Faisal Specialist Hospital and Research Center is one of the leading hospital in the region in providing novel CAR T-cell therapy for management of challenging cases of relapsed and or refractory B-ALL, and has delivered a large number of products given its excellence reputation and the large number of cases treated at the center. We aim through our study to analyze the correlation between CD19 expression across the realm of B-ALL hierarchy using samples from relapsed B-ALL patients who underwent CAR T-cells therapy at our center and weigh this against their outcomes in relation to the percent expression of CD19 at each cellular faction: CD34+CD38-, CD34+CD38+, and CD34-CD38+.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia

NCT01974479

B-cell Acute Lymphoblastic Leukemia

SUSPENDED PHASE1

Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia

NCT06184009

Pediatric Acute Lymphoblastic Leukemia

RECRUITING PHASE2

Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia

NCT01678508

Acute Lymphoblastic Leukemia

COMPLETED

Adipokines as Predictors of the Metabolic Syndrome in ALL Survivors

NCT00566566

Leukemia Metabolic Syndrome X

UNKNOWN

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

NCT05679895

T-cell Acute Lymphoblastic Leukemia Lymphoblastic T-Cell Lymphoma

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsed B-ALL CAR T-cells CD19-directed CAR T-cell Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All patients (adults and Pediatrics)

This is a retrospective observational study analyzing archived flow cytometry data from all patients diagnosed with B-ALL who subsequently received CD19-directed CAR T-cell therapy since the inception of the program.

Study Criteria (all of the following):

1. Confirmed diagnosis of B-ALL
2. Receipt of CD19-targeted CAR T-cell therapy
3. Availability of diagnostic or post-treatment bone marrow or peripheral blood samples processed with a standard B-ALL immunophenotyping panel.
4. Presence of CD45, CD19, CD34, and CD38 in the antibody panel.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All patients (adults and pediatrics) with confirmed diagnosis with B-ALL and receipt CD19-targeted CAR-T cell therapy and have diagnostic or post -treatment BM or PB samples processed with a standard B-ALL immunophenotyping panel. with the presence of CD45, CD19, CD34, and CD38 in the antibody panel.

Eligible Sex

ALL

Accepts Healthy Volunteers

No